Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Development of novel drugs for human African trypanosomiasis.

Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP.

Future Microbiol. 2011 Jun;6(6):677-91. doi: 10.2217/fmb.11.44. Review.

2.

Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.

Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazué G, Bray MA, Pécoul B.

PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923. doi: 10.1371/journal.pntd.0000923.

3.

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.

Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, Gaukel EG, Orr MD, Perales JB, Jenks M, Noe RA, Sligar JM, Zhang YK, Bacchi CJ, Yarlett N, Don R.

Future Med Chem. 2011 Aug;3(10):1259-78. doi: 10.4155/fmc.11.80.

PMID:
21859301
4.

Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.

Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R.

Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8. doi: 10.1128/AAC.00246-11. Epub 2011 Sep 12.

5.

Do we need new drugs against human African trypanosomiasis?

Stich A, Ponte-Sucre A, Holzgrabe U.

Lancet Infect Dis. 2013 Sep;13(9):733-4. doi: 10.1016/S1473-3099(13)70191-9. No abstract available.

PMID:
23969207
6.

Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).

Tweats D, Bourdin Trunz B, Torreele E.

Mutagenesis. 2012 Sep;27(5):523-32. doi: 10.1093/mutage/ges015. Epub 2012 Apr 26.

PMID:
22539226
7.

Fexinidazole: a potential new drug candidate for Chagas disease.

Bahia MT, de Andrade IM, Martins TA, do Nascimento ÁF, Diniz Lde F, Caldas IS, Talvani A, Trunz BB, Torreele E, Ribeiro I.

PLoS Negl Trop Dis. 2012;6(11):e1870. doi: 10.1371/journal.pntd.0001870. Epub 2012 Nov 1.

8.

Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.

Thuita JK, Wolf KK, Murilla GA, Bridges AS, Boykin DW, Mutuku JN, Liu Q, Jones SK, Gem CO, Ching S, Tidwell RR, Wang MZ, Paine MF, Brun R.

PLoS Negl Trop Dis. 2015 Feb 5;9(2):e0003409. doi: 10.1371/journal.pntd.0003409. eCollection 2015 Feb.

9.

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.

Cleghorn LA, Albrecht S, Stojanovski L, Simeons FR, Norval S, Kime R, Collie IT, De Rycker M, Campbell L, Hallyburton I, Frearson JA, Wyatt PG, Read KD, Gilbert IH.

J Med Chem. 2015 Oct 8;58(19):7695-706. doi: 10.1021/acs.jmedchem.5b00596. Epub 2015 Sep 29.

10.

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections.

Don R, Ioset JR.

Parasitology. 2014 Jan;141(1):140-6. doi: 10.1017/S003118201300142X. Epub 2013 Aug 28. Review. Erratum in: Parasitology. 2014 Jan;141(1):147.

PMID:
23985066
11.

Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.

Burrell-Saward H, Harris AJ, de LaFlor R, Sallam H, Alavijeh MS, Ward TH, Croft SL.

Int J Antimicrob Agents. 2017 Aug;50(2):203-209. doi: 10.1016/j.ijantimicag.2017.01.038. Epub 2017 May 25.

PMID:
28552771
12.

Control and surveillance of human African trypanosomiasis.

World Health Organization.

World Health Organ Tech Rep Ser. 2013;(984):1-237.

PMID:
24552089
13.

Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.

Abdeen S, Salim N, Mammadova N, Summers CM, Goldsmith-Pestana K, McMahon-Pratt D, Schultz PG, Horwich AL, Chapman E, Johnson SM.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5247-5253. doi: 10.1016/j.bmcl.2016.09.051. Epub 2016 Sep 22.

PMID:
27720295
14.

Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.

Thuita JK, Wolf KK, Murilla GA, Liu Q, Mutuku JN, Chen Y, Bridges AS, Mdachi RE, Ismail MA, Ching S, Boykin DW, Hall JE, Tidwell RR, Paine MF, Brun R, Wang MZ.

PLoS Negl Trop Dis. 2013 Jun 6;7(6):e2230. doi: 10.1371/journal.pntd.0002230. Print 2013.

15.

Identification of Trypanosoma brucei leucyl-tRNA synthetase inhibitors by pharmacophore- and docking-based virtual screening and synthesis.

Zhao Y, Wang Q, Meng Q, Ding D, Yang H, Gao G, Li D, Zhu W, Zhou H.

Bioorg Med Chem. 2012 Feb 1;20(3):1240-50. doi: 10.1016/j.bmc.2011.12.035. Epub 2011 Dec 30.

PMID:
22249121
16.

Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis.

Rodgers J, Jones A, Gibaud S, Bradley B, McCabe C, Barrett MP, Gettinby G, Kennedy PG.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1308. doi: 10.1371/journal.pntd.0001308. Epub 2011 Sep 6.

17.

Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.

Faria J, Moraes CB, Song R, Pascoalino BS, Lee N, Siqueira-Neto JL, Cruz DJ, Parkinson T, Ioset JR, Cordeiro-da-Silva A, Freitas-Junior LH.

J Biomol Screen. 2015 Jan;20(1):70-81. doi: 10.1177/1087057114556236. Epub 2014 Oct 23.

PMID:
25342146
18.

In vitro and in vivo anti-Trypanosoma brucei activities of phenazinomycin and related compounds.

Otoguro K, Ishiyama A, Iwatsuki M, Namatame M, Nishihara-Tukashima A, Nakashima T, Shibahara S, Kondo S, Yamada H, Omura S.

J Antibiot (Tokyo). 2010 Sep;63(9):579-81. doi: 10.1038/ja.2010.72. Epub 2010 Jun 30. No abstract available.

PMID:
20588299
19.

Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.

González M, Cerecetto H.

Expert Opin Ther Pat. 2011 May;21(5):699-715. doi: 10.1517/13543776.2011.565334. Epub 2011 Mar 24. Review.

PMID:
21428846
20.

Drug discovery and human African trypanosomiasis: a disease less neglected?

Ferrins L, Rahmani R, Baell JB.

Future Med Chem. 2013 Oct;5(15):1801-41. doi: 10.4155/fmc.13.162. Review.

PMID:
24144414

Supplemental Content

Support Center